TABLE 1.
Baseline demographics and clinical characteristics of 27 GC patients.
| Characteristic | Case (%) |
|---|---|
| Age | |
| ≥ 65 years | 6 (22.2) |
| < 65 years | 21 (77.8) |
| Sex | |
| Male | 21 (77.8) |
| Female | 6 (22.2) |
| MSI status | |
| MSS/MSI‐L | 26 (96.3) |
| MSI‐H | 1 (3.7) |
| PD‐L1 status | |
| Negative | 21 (77.8) |
| Positive | 5 (18.5) |
| N/A | 1 (3.7) |
| EBV status | |
| Negative | 16 (59.3) |
| Positive | 3 (11.1) |
| N/A | 8 (29.6) |
| Lauren classification | |
| Diffuse | 1 (3.7) |
| Intestinal | 4 (14.8) |
| Mixed | 3 (11.1) |
| N/A | 19 (70.4) |
| Liver metastasis | |
| No | 19 (70.4) |
| Yes | 8 (29.6) |
| ECOG performance status | |
| 0 | 12 (44.4) |
| 1 | 15 (55.6) |
| Baseline LDH | |
| Normal | 19 (70.4) |
| Abnormal | 6 (22.2) |
| N/A | 2 (7.4) |
| Tumor burden a | |
| ≤ 100 mm | 18 (66.7) |
| > 100 mm | 9 (33.3) |
| Prior Lines of treatment | |
| 1 | 7 (25.9) |
| 2 | 8 (29.6) |
| ≥ 3 | 12 (44.4) |
| TMB status | |
| ≥ 12 Muts/Mb | 8 (29.6) |
| < 12 Muts/Mb | 19 (70.4) |
| Best Response | |
| PR | 7 (25.9) |
| SD | 11 (40.7) |
| PD | 9 (33.3) |
a
Indicated as the sum of the longest diameter of the target lesions at baseline.
Abbreviations: MSI, microsatellite instability; PD‐L1, programmed death‐ligand 1; EBV, Epstein‐Barr virus; ECOG, electrocorticography; LDH, lactate dehydrogenase; TMB, tumor mutation burden; PD, progressive disease; SD, stable disease; PR, partial response; GC, gastric cancer; N/A, not available.